Acadia Pharmaceuticals Inc. (ACAD)

[north40000]

ACAD sales reps may have switched to using ZM or Teledoc to contact hospital or doctor or even pharmacy customers. Amarin IHub board has various folks, mostly doctors, reporting such contacts by AMRN reps. Its drug, Vascepa, received FDA approval for treatment of various CVDs in mid December 2019 with an expanded label reflecting results of its 8000+ patient Reduce-It clinical trial. Amarin sales force also was increased from 400 to 800 reps.

Amarin share price was mostly up last week. It is recovering from a one day steep drop caused by a litigation decision by a judge in Reno, Nevada that is being appealed. In addition to patents granted by PTO, FDA granted Vascepa a 3-year statutory “exclusivity” status that expires in December 2022 for the new indications of use ensuing from Reduce-It trial—that trial has a far larger market than the use from older Marine clinical trial.

I do not intend to sell any of our shares of ACAD or AMRN.